Download Now: Precision September Events Calendar
Check out our September Events Calendar, and stay up to date with all of the upcoming and on-demand Precision events and thought leadership!
Check out our September Events Calendar, and stay up to date with all of the upcoming and on-demand Precision events and thought leadership!
Don’t miss any of our upcoming Precision Value & Health events! Check out our monthly marketing activities calendar to stay ahead of upcoming dates!
In this new downloadable brief, PRECISIONadvisors experts Katherine Leong and David Carr provide a quick overview of the current digital therapeutics landscape in Europe, taking a closer look at the rapidly-expanding list of interventions as well as the varied ways that EU countries are approaching policy, regulation and reimbursement.
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
Watch our panel of industry experts discuss the future of advanced medicines with emerging technologies like gene editing, non-viral delivery methods, and allogeneic cell therapies. Watch Here!
Did you see our poster presentations at this year's ISPOR conference in Washington, DC?
Attending World EPA Congress March 22-24 in Amsterdam? Don’t miss PRECISIONadvisors Richard Macaulay and David Carr present “Gene Therapies Market Access: Lessons From The Past, Future Best Practice” March 23 at 11:45 CET, and be sure to stop by our booth to speak with one of our experts.
We’re excited to announce that the PRECISIONadvisors team will be presenting 2 podium presentations and 7 posters at Virtual ISPOR Europe 2021 30 November- 3 December.
There is no doubt that the advanced therapies sector is growing at an exponential rate. According to a recently published 2021 Report by ARM (Alliance for Regenerative Medicine), the sector has raised $14.1B in financing in the first half of 2021 which is already 71% of what was raised in all of 2020. In addition, there are over 2,600 advance therapy clinical trials being conducted with 264 of those trails being Phase 3 trials and another 1,500 being Phase 2 trials.
The promise of cell-based immunotherapy is giving hope to patients around the globe living with devastating disease; but the future of the cell therapy industry is still unclear. This panel discussion co-hosted by Precision for Medicine and Precision ADVANCE will feature key insights and discussion from advanced therapy leaders on the pros and cons of developing Autologous and Allogeneic cell therapies.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ